scholarly journals Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic

2021 ◽  
Vol 17 (2) ◽  
pp. 228-232
Author(s):  
S. M. Mamatov ◽  
B. Kanat kyzy ◽  
A. O. Musakeev ◽  
N. K. Kinderbaeva ◽  
T. J. Tagaev
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Practice ◽  
Family Medicine ◽  
Anticoagulant Therapy ◽  
Antithrombotic Therapy ◽  
Antiplatelet Agents ◽  
The Elderly ◽  
Kyrgyz Republic ◽  
The Republic ◽  
Real Picture

Aim. To study the current state of the anticoagulant's prescription in elderly and senile patients with atrial fibrillation in the clinical practice of family medicine center, in the southern regions of the Kyrgyz Republic.Material and methods. Of the 1974 ambulatory medical observation cards, 470 patients with atrial fibrillation were selected who had indications for prescribing antithrombotic therapy (87 [18.5%] men and 383 [81.5%] women; 212 [45.1%] urban residents and 258 [54.9%] rural residents). The average age was 66.9±10.2 years. The analysis included data from 387 patients who received anticoagulant therapy. The frequency of prescribing antithrombotic therapy has been studied.Results. There were indications for anticoagulant therapy in 387 patients. Anticoagulants were taken by 167 (43.2%) patients, antiplatelet agents - 196 (50.6%), no therapy - 24 (6.2%). Anticoagulant therapy in 153 patients included warfarin, while only 11.8% had adequate INR control after one year of follow-up. Rivaroxaban was prescribed in 14 (8.4%) patients. 50% of patients had antiplatelet agents instead of anticoagulants, which were mainly prescribed by therapists of rural family medicine centers.Conclusion. In the southern regions of the republic, an unfavorable situation is observed with the prescription and management of elderly and senile patients on anticoagulant therapy. It is necessary to continue the research across the country in order to obtain a complete and real picture of the problem, and to develop a unified and relevant recommendation.

Analysis of antithrombotic therapy in the elderly patients in clinical practice of family medicine centers of the Kyrgyz Republic

2021 ◽  
Author(s):  
К.К. Базира ◽  
Ф.О. Мусакеев ◽  
Н.К. Киндербаева ◽  
У.К. Кундашев ◽  
У.Ч. Мамажакып ◽  
...  
Keyword(s):  
Family Medicine ◽  
Antiplatelet Therapy ◽  
Anticoagulant Therapy ◽  
Antithrombotic Therapy ◽  
Primary Care Physicians ◽  
The Elderly ◽  
Kyrgyz Republic ◽  
Current State ◽  
The Republic ◽  
Real Picture

Введение. Риски тромбоза и кровотечения с возрастом увеличиваются одновременно, при этом пожилой контингент извлекает больше пользы от антитромботической терапии, чем лица молодого возраста. Цель исследования: изучить ситуацию с назначением антикоагулянтной терапии у пациентов пожилого и старческого возраста с фибрилляцией предсердий (ФП) при центрах семейной медицины южных регионов Кыргызской Республики. Материалы и методы. Из 2000 амбулаторных карт медицинского наблюдения отобрано 470 пациентов с неклапанной ФП, которые имели показания для назначения антитромботической терапии: 187 (39,8%) мужчин, 283 (60,2%) женщины, из них 212 (45,1%) городских жителей и 258 (54,9%) сельских жителей. Средний возраст обследованных составил 69,5 ± 10,2 лет. Результаты. Из 377 (80,2%) пациентов должная антикоагулянтная терапия была назначена 162 (42,9%), антиагрегантная терапия — 191 (50,6%), и терапия не была назначена 24 (6,4%) больным при наличии абсолютных показаний. В качестве антикоагулянтной терапии 148 больным был назначен варфарин, адекватная антикоагуляция к концу года составила всего 12,2%. Новый оральный антикоагулянт — ривароксабан был назначен 14 (8,6%) пациентам. Врачами-терапевтами сельской местности 50% больным при необходимости антикоагулянтов была назначена антиагрегантная терапия. Заключение. В южных регионах республики наблюдается неблагоприятная ситуация с назначением антикоагулянтной терапии и ведением пациентов пожилого и старческого возраста. Необходимо продолжить исследования по другим регионам страны для получения полноценной и реальной картины по проблеме и выработки единой и соответствующей рекомендации. Background. The risks of thrombosis and bleeding increase simultaneously with age. At the same time, the elderly population derives more benefit from antithrombotic therapy than young individuals. Objectives: to study the current state of the anticoagulant therapy prescription for elderly and senile patients with atrial fibrillation (AF) at the centers of family medicine in the southern regions of the Kyrgyz Republic. Patients/Methods. From 2000 outpatient medical records, 470 patients with nonvulvar AF were selected who had indications for prescribing antithrombotic therapy: 187 (39.8%) men, 283 (60.2%) women; 212 (45.1%) were urban residents and 258 (54.9%) were village residents. The average age was 69.5 ± 10.2 years. Results. From among 377 (80.2%) patients, needful anticoagulant therapy was prescribed to 162 (42.9%), 191 (50.6%) patients received antiplatelet therapy and therapy was not prescribed to 24 (6.4%) patients in the presence of absolute indications. Warfarin as anticoagulant therapy was prescribed to 148 patients; adequate anticoagulation by the end of the year was only 12.2%. A new oral anticoagulant — rivaroxaban was prescribed to 14 (8.6%) patients. In non-urban area primary care physicians prescribed antiplatelet therapy to 50% of patients who needed anticoagulants. Conclusions. An unfavorable situation is observed with the prescription of anticoagulant therapy and management of elderly and senile patients in the southern regions of the republic. It is necessary to continue study in other regions of the country in order to obtain a complete and real picture of the problem, and to develop a unified and relevant recommendation.

scholarly journals Antithrombotic Therapy in Elderly Patients with Atrial Fibrillation: The State of the Problem in the Real Clinical Practice of a Family Medicine Doctor

2021 ◽  
Vol 6 (2) ◽  
pp. 63-69
Author(s):  
Bazira Kanat кyzy ◽  
N. K. Kinderbaeva ◽  
S. O. Turdaliyev ◽  
Zh. A. Mahmudova ◽  
U. K. Kundashev ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Practice ◽  
Family Medicine ◽  
Anticoagulant Therapy ◽  
Antithrombotic Therapy ◽  
Age Groups ◽  
Target Range ◽  
Specialized Team ◽  
Real Clinical Practice

Introduction. The research aimed at studying the efficacy and safety of anticoagulant therapy in patients with atrial fibrillation (AF), especially in older age groups, is now increasingly relevant.The aim of the study is to analyze the situation with prescribing anticoagulant therapy in elderly and senile persons with atrial fibrillation in real clinical practice and to demonstrate the possibility of improving the quality of observation and management of a group of patients as part of the work of a specialized team.Materials and methods. A total of 2,770 medical records of outpatient patients with atrial fibrillation were studied for the period from 2017 to 2019. Of this number, 320 patients with AF of nonvalvular etiology were selected, the average age of which was 70.3 ± 8.15 years. There were 270 women and 50 men. An observational prospective study in 45 elderly and senile patients with AF of non-valvular etiology was carried out by a team of specialized doctors for 12 months.Results. Of the 301 patients, anticoagulant therapy was prescribed to 166 (55.1 %), of which only 17 (10.2 %) people received proper anticoagulant therapy. The excessive activity was observed in 114 (37.9 %) patients, who underwent antiplatelet therapy with aspirin, and 21 (7.0 %) patients remained without any treatment with anticoagulants nor antiplatelet agents. Although, in the case of both, prescribing aspirin and not prescribing, anticoagulants have been indicated. In the prospective part of the study (for 12 months), all 45 patients continued to take anticoagulants and were systematically monitored. The INR in the target range over 60 % of the time was achieved in 37 % of patients receiving warfarin therapy.Conclusion. In the actual clinical practice of Kyrgyzstan family medicine centers, older patients with atrial fibrillation receive inadequate antithrombotic therapy. The main drug of choice for specialists remains warfarin, a therapy that can be recognized as adequate only in a small number (16 %) of patients. The ability to improve the quality of surveillance and management of a group of patients with AF and high adherence to treatment was demonstrated by the work of a specialized team of doctors. 

Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease

2021 ◽  
Author(s):  
Aaron M. Gusdon ◽  
Salia Farrokh ◽  
James C. Grotta
Keyword(s):  
Atrial Fibrillation ◽  
Cardiovascular Disease ◽  
Antithrombotic Therapy ◽  
Antiplatelet Agents ◽  
Left Ventricular ◽  
Optimal Treatment ◽  
Ventricular Assist Devices ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Nonbacterial Thrombotic Endocarditis

AbstractPrevention of ischemic stroke relies on the use of antithrombotic medications comprising antiplatelet agents and anticoagulation. Stroke risk is particularly high in patients with cardiovascular disease. This review will focus on the role of antithrombotic therapies in the context of different types of cardiovascular disease. We will discuss oral antiplatelet medications and both IV and parental anticoagulants. Different kinds of cardiovascular disease contribute to stroke via distinct pathophysiological mechanisms, and the optimal treatment for each varies accordingly. We will explore the mechanism of stroke and evidence for antithrombotic therapy in the following conditions: atrial fibrillation, prosthetic heart values (mechanical and bioprosthetic), aortic arch atherosclerosis, congestive heart failure (CHF), endocarditis (infective and nonbacterial thrombotic endocarditis), patent foramen ovale (PFO), left ventricular assist devices (LVAD), and extracorporeal membrane oxygenation (ECMO). While robust data exist for antithrombotic use in conditions such as atrial fibrillation, optimal treatment in many situations remains under active investigation.

scholarly journals Changes in Prescribing Antithrombotic Therapy in Patients with Atrial Fibrillation in the Multidisciplinary Hospital in Volgograd from 2012 to 2020

2022 ◽  
Vol 17 (6) ◽  
pp. 831-836
Author(s):  
A. S. Gerasimenko ◽  
O. V. Shatalova ◽  
V. S. Gorbatenko ◽  
V. I. Petrov
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Practice ◽  
Clinical Guidelines ◽  
Antithrombotic Therapy ◽  
Heart Valves ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
International Normalized Ratio ◽  
Prosthetic Heart Valves ◽  
Discharge From Hospital

Aim. To study the frequency of prescribing antithrombotic agents in patients with non-valvular atrial fibrillation (AF) in real clinical practice, to evaluate changes of prescriptions from 2012 till 2020.Material and methods. The medical records of inpatients (Form 003/y) with the diagnosis AF, hospitalized in the cardiological department were analyzed. According to the inclusion criteria, the patients were over 18 years of age, established diagnosis of non-valvular AF. There were two exclusion criteria: congenital and acquired valvular heart disease and prosthetic heart valves. In retrospective analysis we have included 263 case histories in 2012, 502 ones in 2016 and 524 in 2020. CHA2DS2-VASc score was used for individual stroke risk assessment in AF. The rational use of the antithrombotic therapy was evaluated according with current clinical practice guidelines at analyzing moment.Results. During period of observation the frequency of antiplatelet therapy significantly decreased from 25,5% to 5,5% (р<0.001), decreased the frequency of administration of warfarin from 71,9% to 18,3% (р<0.001). The frequency of use of direct oral anticoagulants increased in 2020 compared to 2016 (р<0.001). For patients with a high risk of stroke anticoagulant therapy was administered in 71.8% of cases in 2012, 88.5% in 2016 and 92.5% in 2020. Before discharge from hospital majority of patients (72%) achieved a desired minimum international normalized ratio (INR) from 2.0 to 3.0 in 2012. In 2016 and 2020 an only 33% and 40.6% of patients achieved INR (2.0-3.0).Conclusion. Doctors have become more committed to following clinical guidelines during the period of the investigation. In 2020 antithrombotic therapy for atrial fibrillation was suitable according to current clinical guidelines.

scholarly journals Amiodarone Toxicity Screening: What are the Clinicians Supposed to Tell Patients

2020 ◽  
pp. 1-5
Author(s):  
John D Rozich ◽  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Clinical Practice ◽  
Kidney Disease ◽  
Low Dose ◽  
The Elderly ◽  
Toxicity Screening ◽  
Nonvalvular Atrial Fibrillation ◽  
Routine Testing ◽  
Continued Use

The use of amiodarone in clinical practice continues to be widespread in the setting of nonvalvular atrial fibrillation (NVAF). Use of amiodarone continues especially in the elderly where the drug’s favorable characteristics and outcomes in the setting of chronic kidney disease coupled to its low inherent proarrhythmic profile has ensured its continued use. The present work focuses on the information that clinicians should tell their patients regarding requisite toxicity screening during daily treatment with amiodarone when it is maintained at a low dose of 200 mgs per day or less. Several questions need be answered in pursuit of the fundamental query as to whether routine testing for toxicity should still be advised. Most importantly, has ongoing screening shown to be of any proven value?

scholarly journals Problem of prescribing anticoagulant therapy in patients with atrial fibrillation on the regional level

2020 ◽  
pp. 19-25
Author(s):  
M. G. Nazarkina ◽  
V. V. Stolyarova ◽  
D. A. Karpova
Keyword(s):  
Atrial Fibrillation ◽  
Anticoagulant Therapy ◽  
Oral Anticoagulants ◽  
Significant Proportion ◽  
Heart Rhythm ◽  
Regional Level ◽  
Thromboembolic Complications ◽  
Constant Form ◽  
Heart Rhythm Disorders ◽  
The Republic

Introduction. Cardiovascular diseases are the leading cause of morbidity and mortality worldwide, with heart rhythm disorders accounting for a significant proportion of them. Atrial fibrillation (AF) is an arrhythmia that poses a risk of thromboembolic complications and is difficult to treat with ongoing preventive anticoagulant therapy. Aim of the study. To analyze the prescription of anticoagulant therapy to patients with AF on the regional level. Methods and results. The study included 72 patients with the nonvalvular form of AF (from 41 to 82 years old) of the Department of Rhythm and Conductivity Abnormalities of the State Budgetary Institution of the Republic of Mordovia RCH № 4 for 2019. Three groups were singled out depending on the AF form: the first one – patients with the constant form (n = 22), the second one (n = 24) – with the persistent form, the third one (n = 24) – with the paroxysmal form. The risk of thromboembolic complications was assessed using the CHA2DS2-VASc scale and hemorrhagic complications using the HAS-BLED scale. All patients had a high risk of thromboembolism (index above 2 points), which reflects multiple risk factors and indicates the need for oral anticoagulants (OAC). According to HAS-BLED scale calculations, the risk of haemorrhagic complications was low in most patients (2 or less points) – there was no significant increase in the risk of bleeding, but careful monitoring is required. Analysis of the results revealed that only 54% of patients took OAC, despite the fact that all patients were shown anticoagulant therapy. When analyzing the cases of patients who did not take anticoagulants, it was found that 23% of patients, despite the doctor’s recommendations, refused to take the drugs, 47% of patients justified the inability to control IHR and 30% were unable to purchase expensive new OAC. Conclusion. Despite the recommendations for the management of patients with atrial fibrillation, only 54% were prescribed oral anticoagulants.

Abstract W P339: Anticoagulation Remains Underutilized in the Management of Atrial Fibrillation: Results From the Edmonton Registry of Atrial Fibrillation and StrokE (ERASE) Study

Stroke ◽  
2014 ◽  
Vol 45 (suppl_1) ◽  
Author(s):  
Ghazala Basir ◽  
Ashfaq Shuaib ◽  
Affan Tahir ◽  
Kasim Qureshi ◽  
Hasnain Zeeshan ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Antithrombotic Therapy ◽  
Oral Anticoagulants ◽  
Antiplatelet Agents ◽  
Tertiary Hospital ◽  
Stroke Patients ◽  
Single Centre ◽  
Chads2 Score ◽  
Similar Frequency ◽  
Prior Stroke

Background: Since 2010, three novel oral anticoagulants (NOAC) have been approved and included in the guidelines as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). Prior to the introduction of NOACs, studies showed that anticoagulation with warfarin in stroke patients with NVAF is suboptimal with as few as 40% anticoagulated and most subtherapeutic. The goal of this study is to examine anticoagulation usage in a contemporary prospective registry of TIA/stroke patients with NVAF and determine whether the introduction of NOACs has increased anticoagulation usage. Methods: This is an ongoing single centre observational study. Consecutive TIA/ischemic stroke admissions (2012-13) to a tertiary hospital in Edmonton, Canada with NVAF were enrolled. Data regarding demographic, clinical, antithrombotic treatment and laboratory parameters were collected in a prospectively maintained database. Those with previously diagnosed NVAF were included in the present analysis (149/181). Clinical characteristics were compared between patients on anticoagulants and those on other/no antithrombotic therapy. Results: The 149 included patients had a mean (SD) age of 78.7 (10.0) years. Male were 52.3% and 86.6% (129) had a preadmission CHADS2 score ≥2. At the time of TIA/stroke, 51% (76/149) were on an anticoagulant, 24.2% (36/149) on antiplatelet agents and 28.4% (37/149) were on no antithrombotic therapy. Of the 76 patients on anticoagulants, 81.6% were on warfarin and the remaining (18.4%) were on a NOAC. Only 31% of patients on warfarin had a therapeutic INR at the time of stroke. Patients not anticoagulated had a similar frequency of prior stroke (21% vs. 23%; p=0.80) but tended to have a lower CHADS2 score (p=0.082) than those anticoagulated. In patients with CHADS≥2, 47% were not on an anticoagulant. Conclusions: Despite therapeutic advances in the treatment of NVAF, anticoagulation usage in TIA/stroke patients with preexisting NVAF remains suboptimal. In this study, only 53% of patients with NVAF and a CHADS≥2 were treated with anticoagulants. This study emphasizes the need for increased efforts to encourage prescribing of oral anticoagulants in high-risk individuals.

scholarly journals Prescription of oral anticoagulants and antiplatelets for stroke prophylaxis in atrial fibrillation: nationwide time series ecological analysis

EP Europace ◽  
2020 ◽  
Vol 22 (9) ◽  
pp. 1311-1319 ◽  
Author(s):  
Jianhua Wu ◽  
Eman S Alsaeed ◽  
James Barrett ◽  
Marlous Hall ◽  
Campbell Cowan ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Stroke Risk ◽  
Oral Anticoagulants ◽  
Temporal Trends ◽  
Antiplatelet Agents ◽  
The Elderly ◽  
Early Years ◽  
Prescription Data ◽  
Ecological Analysis ◽  
General Practices

Abstract Aims To investigate trends in the prescription of oral anticoagulants (OACs) and antiplatelet agents for atrial fibrillation (AF). Methods and results Prescription data for 450 518 patients with AF from 3352 General Practices in England, was obtained from the GRASP-AF registry, 2009–2018. Annualized temporal trends for OAC and antiplatelet prescription were reported according to eligibility based on stroke risk (CHADS2 or CHA2DS2-VASc scores ≥1 or &gt;2, respectively). From 2009 to 2018, the prevalence of AF increased from 1.6% [95% confidence interval (CI) 1.5–1.7%] to 2.4% (2.3–2.5%), and for those with AF the proportion prescribed OAC increased from 47.6% to 75.0% (P-trend &lt; 0.001; relative risk 1.57, 95% CI 1.55–1.60) and for antiplatelet decreased from 37.4% to 9.2% (P-trend &lt; 0.001). In early-years (2009–2013), eligible patients aged ≥80 years were less likely to be prescribed OAC than patients aged &lt;80 years [odds ratio (OR) 0.55, 95% CI 0.51–0.59 for CHADS2≥1 in 2009] (all P-trends &lt; 0.001). This ‘OAC prescription gap’ reduced over the study period (OR 0.93, 0.90–0.96 in 2018). Whilst the prescription of direct oral anticoagulant (DOAC) as a proportion of all OAC increased from 0.1% (95% CI 0.0–0.2%) in 2011 to 58.8% (58.4–59.2%) in 2018, it was inversely associated with patient age (P-trend &lt; 0.001) and their risk of stroke. Conclusion Between 2009 and 2018, in England, the use of OAC for stroke prophylaxis in AF increased, with DOAC accounting for over half of OAC uptake in 2018. Despite a reduction in the OAC-prescription gap, a new paradox exists relating to DOAC prescription for the elderly and those at higher risk of stroke.

Sign in / Sign up

Export Citation Format

Share Document